# US 2019/0153390 A1 · COMPOSITION FOR PROMOTING MATURATION OF DENDRITIC CELL CONTAINING FUSION PROTEIN OF Rv2299c AND ESAT-6

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0153390 A1
- Document ID: US20190153390A1
- Status: Published application
- Kind: A1
- Application number: 16/204,436
- Filed: 2018-11-29
- Published: 2019-05-23
- Earliest claimed: 2016-06-07
- Assignees: Quratis Inc.
- Applicants: Quratis Inc.
- Inventors: Hwa-Jung Kim; Han-Gyu Choi; Sung Jae Shin
- Web page: https://patentgrep.com/patent/US20190153390A1

## CPC

- C07K 14/35: from Mycobacteriaceae (F)
- A61K 38/16: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)}
- A61K 40/19: Dendritic cells
- A61K 40/24: Antigen-presenting cells [APC]
- A61K 40/428: {Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor}
- A61K 40/4524: {Mycobacterium, e.g. Mycobacterium tuberculosis}
- A61P 37/04: Immunostimulants
- C12N 5/0639: {Dendritic cells, e.g. Langherhans cells in the epidermis}
- C07K 2319/00: Fusion polypeptide
- C12N 2501/998: Proteins not provided for elsewhere
- C12N 2506/11: from blood or immune system cells
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to a composition for inducing dendritic cell maturation and a method for maturing dendritic cells. More particularly, the present invention relates to a composition including a fusion protein of Rv2299c and ESAT-6, both derived from M. tuberculosis, as an active ingredient for inducing dendritic cell maturation, and a method for differentiating immature dendritic cells into dendritic cells by using the same. The method of the present invention can increase a dendritic cell immune response in the body.

## Claims

### Claim 1

A composition for inducing maturation of dendritic cells, the composition comprising a fusion protein of Rv2299c and ESAT-6 as an active ingredient.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the fusion protein of Rv2299c and ESAT-6 is a protein derived from M. tuberculosis.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the fusion protein of Rv2299c and ESAT-6 is included at a concentration of 1 μg/ml to 20 μg/ml.

### Claim 4

A method for inducing maturation of immature dendritic cells, the method comprising:
(a) differentiating mononuclear cells isolated from blood into immature dendritic cells; and
(b) treating the immature dendritic cells with a fusion protein of Rv2299c and ESAT-6 to mature the immature dendritic cells into mature dendritic cells.

### Claim 5 (depends on 4)

The method of claim 4, wherein after treating the immature dendritic cells with the fusion protein of Rv2299c and ESAT-6, the cells are cultured for 12 hours to 36 hours.

### Claim 6 (depends on 4)

The method of claim 4, wherein the fusion protein of Rv2299c and ESAT-6 increases the production of at least one selected from the group consisting of TNF-α, IL-12p70, IL-6 and IL-1β during the maturation of immature dendritic cells.

### Claim 7 (depends on 4)

The method of claim 4, wherein the fusion protein of Rv2299c and ESAT-6 is included at a concentration of 1 μg/ml to 20 μg/ml.

### Claim 8 (depends on 4)

The method of claim 4, wherein the maturation of the immature dendritic cells is caused by stimulation of TLR (toll-like receptor)-4 with the fusion protein of Rv2299c and ESAT-6.

### Claim 9 (depends on 4)

The method of claim 4, wherein the maturation of immature dendritic cells is caused by stimulation of mitogen-activated protein kinase (MAPK) and NF-κB.

### Claim 10 (depends on 1)

A composition for enhancing immunity, the composition comprising the composition of claim 1.

### Claim 11 (depends on 2)

A composition for enhancing immunity, the composition comprising the composition of claim 2.
